Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

Core Insights - Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals, valued at approximately $3.71 million, as per a February 2 SEC filing [1][2] - The fund's overall position in Arrowhead increased in value by $10.09 million due to significant price appreciation during the quarter [2] - Arrowhead's stock price reached $73.00, reflecting a remarkable 289.5% increase year-over-year, significantly outperforming the S&P 500's 15% gain in the same period [3] Company Overview - Arrowhead Pharmaceuticals specializes in RNAi-based therapeutics for serious and rare diseases, with a strong clinical-stage pipeline and strategic collaborations [5][6] - The company reported a total revenue of $829.45 million and a net income of -$1.6 million, with a market capitalization of $10.22 billion [4] - Arrowhead's revenue surged from $3.6 million to $829 million in fiscal 2025, primarily due to licensing and milestone payments, while operating income improved to a profit of $98 million from a loss of $612 million the previous year [8] Investment Implications - The FDA's approval of Arrowhead's first commercial drug, REDEMPLO, marks a significant milestone for the company, enhancing its financial outlook and operational flexibility with total cash resources of $782 million [8] - The recent stock performance, climbing nearly 60% since the earnings release, indicates strong market confidence, while the decision to trim holdings reflects a strategy of risk management and disciplined investment [9]